Evidence map›Paper›PMID 40773483›Full record

ArticlePloS one2025

Wasting and short-term outcomes among children with cancer in resource-limited settings: A prospective study in Uganda.

Richard Nyeko, Jaques van Heerden, Joyce Balagadde Kambugu, Fadhil Geriga, Racheal Angom, Teresa de Rojas, Anouk Neven

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Richard NyekoDepartment of Pediatric and Child Health, Faculty of Medicine, Lira University, Lira, Uganda.ORCID https://orcid.org/0000-0003-3859-349X
Jaques van HeerdenPediatric Oncology Service, Uganda Cancer Institute, Kampala, Uganda.
Joyce Balagadde KambuguPediatric Oncology Service, Uganda Cancer Institute, Kampala, Uganda.
Fadhil GerigaPediatric Oncology Service, Uganda Cancer Institute, Kampala, Uganda.
Racheal AngomPediatric Oncology Service, Uganda Cancer Institute, Kampala, Uganda.
Teresa de RojasArztpraxis Mylife, Fulenbach, Solothurn, Switzerland.
Anouk NevenLuxembourg Institute of Health, Competence Center for Methodology and Statistics, Strassen, Luxembourg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWasting contributes to poor treatment outcomes in children with cancer, especially in low-resource settings. In these settings, there is inadequate routine, systematic assessment of the wasting status of children with cancer. Wasting is diagnosed based on visual evidence, with a subjective bias for recognition. This study determined the prevalence of wasting at diagnosis among children with cancer at the Uganda Cancer Institute (UCI) and the diagnostic accuracy of "visible wasting" in identifying children with wasting as measured by anthropometric indices, and identified predictors of 6-months negative outcomes.

methodsWe assessed the wasting status at diagnosis, diagnostic accuracy of visible wasting, and 6-month outcomes of children newly diagnosed with cancer at the UCI (both ambulatory and hospitalized) between April 2022 and March 2023. Data were analyzed using SPSS version 26. Descriptive, bivariate, multivariate, and survival analyses were performed as appropriate. Statistical significance was determined at P-value<0.05.

resultsOne hundred forty-four children with cancer, with a median age of 10.0 years (interquartile range [IQR] 4.0-14.0 years), were included. The majority, 89 (61.8%), had solid tumor, whereas 55 (38.2%) had hemato-lymphoid malignancies. Thirty-two (22.2%) of the participants had visible wasting, and 57 (39.6%) were wasted based on anthropometric measurements, 32 (56.1%) of whom showed no visible wasting. Visible wasting had a low sensitivity of 43.9% (95% CI 30.7-57.6) - ROC 0.32 (95% CI 0.23-0.42), with a false negative rate of 56.1%. Overall, visible wasting missed up to 80.6% (25/31) of children with moderate wasting and 26.9% (7/26) with severe wasting. Twenty-one (14.6%) of the patients died, 8 (38.1%) of whom were deemed to be wasted, and 15 (71.4%) had anthropometrically-defined wasting. Neutropenia occurred in 20.8% (n = 30) of the participants and sepsis in 13.9% (n = 20). In univariate analyses, wasted patients were more likely to develop neutropenia (OR 3.63; 95% CI 1.56-8.42; p = 0.003), sepsis (OR 4.50; 95% CI 1.65-12.29; p = 0.003), and die (OR 3.08; 95% CI 1.15-8.28; p = 0.026).

conclusionWasting at diagnosis is a common problem among children with cancer in this resource-limited setting and is associated with increased risks of neutropenia, sepsis, and mortality. Reliance on visible wasting as a marker for wasting misses other wasted children, some of who may be malnourished and at risk of poor outcome. For accurate categorization of wasting, all patients should undergo a standard anthropometric evaluation.

Indexed as

NeoplasmsWasting SyndromeAdolescentChildChild, PreschoolFemaleHealth ResourcesHumansMalePrevalenceProspective StudiesResource-Limited SettingsUganda

Identifiers

PMID40773483
PMCPMC12331082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.